Use of thiazole derivatives and analogues in the treatment of cancer

A method of treating cancer which comprises administering, to a subject in need of such treatment, an effective amount of a compound of formula I,

• wherein
• X represents —[C(R8)(R9)]n—;
• n represents 0, 1, 2 or 3;
• Y represents —C(O)—, —S(O)2— or ═C(R10)—;
• T represents —S— or —O—;
• W represents —NR7—, —CR7R7—, —NR7C(O)—, —NR7S(O)2—, —NR7C(O)NR7—, —NR7C(O)O— or a bond;
• one of A1 or A2 represents a double bond and the other represents a single bond;
• when A1 represents a single bond, A2 is a double bond and R6 is absent;
• when A2 represents a single bond, A1 is a double bond and, if present, one R7 (which is attached α to the requisite ring of the compound of formula I) is absent;
• R1 represents —C(O)NR3R2, —NR3R2, —C(O)OR2, —NR4C(O)NR3R2, —NR4C(O)OR2, —OC(O)NR3R2, —NR4C(O)R2, —OC(O)R2, —OR2, —SR2, H, alkyl, cycloalkyl, heterocyclyl, benzyl, aryl or heteroaryl (which latter six groups are optionally substituted by one or more groups selected from B1, B2, B3, B4, B5 and B6, respectively);
• R2 and R5 independently represent hydrogen, alkyl, cycloalkyl, heterocyclyl, benzyl, aryl or heteroaryl (which latter six groups are optionally substituted by one or more groups selected from B7, B8, B9, B10, B11 and B12, respectively);
• R3, R4, R6 and R7 independently represent hydrogen, alkyl, cycloalkyl, aryl or benzyl (which latter four groups are optionally substituted by one or more groups selected from B13, B14, B15 and B16, respectively), or heterocyclyl or heteroaryl (which latter two groups are optionally substituted by one or more groups selected from B14 and B15, respectively);
• R8 and R9 are independently selected from hydrogen, alkyl and aryl (which latter two groups are optionally substituted by B16a and B16b, respectively);
• R10 represents hydrogen, alkyl or aryl (which latter two groups are optionally substituted by one or more groups selected from B17 and B18, respectively);
• B1 to B18 independently represent cyano, —NO2, halo, —OR11, —NR12R13, —SR14,
• —Si(R15)3, —C(O)OR16, —C(O)NR16aR16b, —S(O)2NR16cR16d, aryl or heteroaryl (which aryl and heteroaryl groups are themselves optionally and independently substituted by one or more groups selected from halo and R17);
• or, alternatively,
• B4, B5, B6, B10, B11, B12, B15, B16, B16b or B18 independently represent R17;
• R11, R12, R13, R14, R16, R16a, R16b, R16c and R16d independently represent H or R17;
• and
• R15 and R17 independently represent C1-6 alkyl optionally substituted by one or more halo atoms,
• or a pharmaceutically-acceptable salt or solvate, or a pharmaceutically functional derivative thereof,
• for the manufacture of a medicament for the treatment of cancer,
• provided that, when n represents 0 and R1 represents an optionally substituted alkyl group, then that alkyl group is saturated.